Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems Inc (TIVC) delivers innovative bioelectronic solutions through its non-invasive microcurrent therapies, most notably the ClearUP Sinus Relief device. This page provides direct access to all official corporate announcements, financial disclosures, and therapeutic development updates.
Investors and healthcare professionals will find chronologically organized press releases covering regulatory milestones, clinical study results, and partnership agreements. Our repository includes quarterly earnings reports, product launch details, and scientific validation updates – all essential for understanding TIVC's position in the health technology sector.
Key focus areas include advancements in bioelectronic treatment platforms, market expansion initiatives, and peer-reviewed research findings. Content is rigorously verified to ensure alignment with SEC filings and medical device regulations. Bookmark this page for efficient tracking of material developments affecting TIVC's therapeutic innovations and business trajectory.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, announced a public offering of 20 million shares at $0.25 each, aiming for approximately $5 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 3 million shares. Proceeds will be used for expanding sales of its product ClearUP® for sinus relief and for clinical and regulatory costs related to new product candidates. The offering is expected to close on February 13, 2023, subject to standard conditions.
Tivic Health Systems, Inc. (TIVC), recognized as the Most Pioneering Bioelectronic Medicine Company of 2022 by Global Health & Pharma, emphasizes the growing field of bioelectronic medicine. CEO Jennifer Ernst highlighted the shift from traditional drug therapeutics to innovative electronic solutions for chronic conditions. The company's ClearUP device, a non-invasive treatment for sinus pain, has earned accolades as the Most Innovative Sinus Relief Solution for two consecutive years. Tivic Health's commitment to evidence-based, non-invasive therapies positions it as a leader in the evolving healthcare landscape.
Tivic Health Systems (Nasdaq: TIVC) has mutually terminated its agreement with Reliefband Technologies regarding the acquisition of the Reliefband product line, initially announced on October 7, 2022. CEO Jennifer Ernst cited volatile capital market conditions as a primary reason for this decision. Despite the setback, the relationship between the two companies remains positive, and Tivic is focused on accelerating sales of its ClearUP product while exploring other growth opportunities.
Tivic Health Systems (TIVC) has hired ALOM Technologies Corporation to enhance its supply chain management, aiming for cost improvements and scalable growth in the bioelectronic medicine sector. ALOM will manage inventory, logistics, and fulfillment from its 19 global locations. This partnership follows a recent agreement with Microart Services Inc. to significantly reduce manufacturing costs by 70% for certain components. Tivic has also increased the MSRP for its ClearUP products by $20 to improve margins.
Tivic Health Systems, Inc. (TIVC) reported a 72% revenue increase in Q3 2022, totaling $477,000, driven by a 130% rise in direct-to-consumer unit sales. Year-to-date revenue increased 65% to $1.4 million, with gross margins improving 22%. The company announced a $33.5 million acquisition of Reliefband Technologies to expand its product offerings, alongside a partnership with Microart Services to reduce manufacturing costs. However, research and development expenses rose significantly, contributing to a net loss of $2.6 million for the quarter.
Tivic Health Systems, Inc. (TIVC) announced it has entered a non-exclusive manufacturing agreement with Microart Services Inc. This partnership aims to significantly reduce product manufacturing and shipping costs. COO Ryan Sabia emphasized that the agreement offers advantageous pricing and enhances scalability while maintaining North American-based production. Tivic Health focuses on bioelectronic medicine, delivering non-invasive treatments for inflammation and related conditions.
Tivic Health, a health technology company focused on bioelectronic medicine, will showcase its FDA-approved ClearUP device at HLTH from November 13-16 in Las Vegas. ClearUP treats sinus pain and congestion caused by colds and allergies. Recently, Tivic announced a definitive agreement to acquire the Reliefband product line for nausea treatment, integrating wearable FDA-cleared therapeutics. The firm aims to enhance consumer awareness of bioelectronic therapies, backed by clinical studies indicating significant symptom reduction.
Tivic Health Systems, a commercial-phase health technology company, is set to announce its third-quarter 2022 financial results via conference call and webcast on November 14, 2022, at 1:30 PM PT.
Shareholders can submit questions until 5:00 PM ET on November 11, 2022. The company specializes in non-invasive bioelectronic treatments aimed at inflammation and related conditions. For more details, visit Tivic Health.
Tivic Health Systems (Nasdaq: TIVC), a leader in bioelectronic medicine, announced that CEO Jennifer Ernst will present at The ThinkEquity Conference on October 26, 2022, in New York City. This event marks a significant opportunity for the company to showcase its innovative, non-invasive treatments for inflammation and related conditions.
The conference will take place at the Mandarin Oriental Hotel, providing a platform for industry insights and networking.
Tivic Health Systems (NASDAQ: TIVC) has announced a definitive agreement to acquire the Reliefband product line, expanding its portfolio in the bioelectronic treatment of nausea. The deal, valued at up to $33.5 million, aims to leverage Reliefband's FDA-cleared products, which cater to a growing market projected at $2.4 billion in the US. This acquisition is anticipated to increase revenue opportunities significantly, combining direct-to-consumer sales with clinical applications.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
